Acurx Pharmaceuticals (ACXP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Sep, 2026Executive summary
Annual meeting scheduled for October 16, 2026, with voting available online and virtually.
Shareholders are encouraged to review proxy materials and vote by October 15, 2026.
Voting matters and shareholder proposals
Election of two Class II directors, David P. Luci and Jack H. Dean, for three-year terms expiring in 2029.
Ratification of CohnReznick LLP as independent registered public accountants for the fiscal year ending December 31, 2026.
Board recommends voting in favor of all proposals.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Board nominees for Class II directorships are presented for shareholder approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Acurx Pharmaceuticals
- Registering 1.5M shares for resale, raising up to $2.8M for R&D, with dilution risk.ACXP
Registration filing - Shareholders will vote virtually on director elections and auditor ratification, with robust governance and oversight.ACXPProxy filing
- Cash rose to $10.7M, net loss narrowed, but new funding is needed for ongoing clinical progress.ACXPQ2 2026
- DNA pol IIIC inhibitors offer potent, selective treatment for resistant Gram-positive infections.ACXPConference presentation
- Phase 3-ready antibiotic ibezapolstat shows high cure rates and strong market potential.ACXPStudy update presentation
- Advanced ibezapolstat trials, improved cash to $9.3M, but cash runway remains short.ACXPQ1 2026
- Up to 1.3M shares registered for resale via equity line, supporting R&D and operations.ACXPRegistration filing
- Registering 1.65M shares for resale, with up to $4.6M possible from warrant exercises.ACXPRegistration filing
- Strong phase II results, cash up, and pivotal Phase 3 trial preparations underway.ACXPQ4 2025